Hipoparatiroidisme

01Pathophysiology

Parathyroid hormone (PTH) is the principal regulator of serum calcium. It acts on three target organs: bone, kidney, and gut (indirectly via vitamin D activation). When PTH is deficient, all three calcium-raising mechanisms fail simultaneously, producing the hallmark biochemical profile of hypocalcemia with hyperphosphatemia.

In bone, PTH normally stimulates osteoclastic resorption to release calcium and phosphate into the bloodstream. Without PTH, this resorption is diminished, reducing one major source of calcium influx. In the kidney, PTH promotes calcium reabsorption in the distal convoluted tubule and phosphate excretion in the proximal tubule. Loss of PTH therefore causes inappropriate urinary calcium wasting (relative to the low serum calcium) and renal phosphate retention, driving serum phosphate upward. The high phosphate further depresses ionized calcium through formation of calcium-phosphate complexes.

PTH also stimulates 1-alpha hydroxylase in the kidney, which converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol), the active form. Without this conversion, intestinal calcium absorption falls dramatically. This is why calcitriol, not cholecalciferol, is the replacement vitamin D form used in hypoparathyroidism.

The resulting hypocalcemia increases neuromuscular excitability. Calcium normally stabilizes voltage-gated sodium channels. When extracellular calcium drops, the threshold potential shifts closer to the resting membrane potential, making neurons fire with less provocation. This explains tetany, muscle spasms, paresthesias, and seizures. The same mechanism prolongs the QT interval on ECG by extending the ST segment, which represents delayed ventricular repolarization.

The most common cause by far is iatrogenic injury or inadvertent removal of the parathyroid glands during thyroid surgery. The onset is typically within 24 to 72 hours postoperatively. Autoimmune destruction of the parathyroid glands occurs either in isolation or as part of autoimmune polyglandular syndrome type 1 (APS-1), which classically presents with hypoparathyroidism, mucocutaneous candidiasis, and adrenal insufficiency. In children, DiGeorge syndrome (22q11.2 microdeletion) causes aplasia or hypoplasia of the parathyroid glands and thymus, resulting in both hypoparathyroidism and T-cell immunodeficiency.

One frequently tested concept is the role of magnesium. Severe hypomagnesemia (serum Mg below 1.0 mg/dL) impairs both PTH secretion and PTH receptor sensitivity. This creates a state of functional hypoparathyroidism that will not respond to calcium replacement until magnesium is corrected first.

02Classification and Clinical Manifestation

Clinical Manifestations by Severity

03Diagnostic Workup

The workup begins with serum total calcium and albumin. Because roughly 40% of circulating calcium is bound to albumin, hypoalbuminemia (common in hospitalized patients) can falsely lower total calcium. The corrected calcium formula or direct measurement of ionized calcium resolves this ambiguity. If ionized calcium is low, the next step is to measure intact PTH.

The PTH level is the critical branch point. In hypoparathyroidism, PTH is low or inappropriately normal in the face of hypocalcemia. A normal PTH when calcium is low is abnormal because the parathyroid glands should be maximally stimulated by low calcium. This distinguishes hypoparathyroidism from other causes of hypocalcemia such as vitamin D deficiency, chronic kidney disease, or pseudohypoparathyroidism, all of which present with elevated PTH (secondary hyperparathyroidism).

Always check serum magnesium alongside calcium. This is one of the most tested points. If magnesium is severely depleted, PTH secretion is impaired and PTH action at the receptor is blunted. The clinical picture mimics hypoparathyroidism with low calcium and low PTH, but the treatment is entirely different: IV magnesium replacement must come first.

Serum phosphate is elevated in hypoparathyroidism because PTH normally promotes phosphaturia. The combination of low calcium + high phosphate + low PTH is the classic biochemical triad. In contrast, vitamin D deficiency causes low calcium + low phosphate + high PTH, because PTH is still functioning and driving renal phosphate wasting.

04Management and Treatment

Acute Management

The first priority in a symptomatic patient (tetany, seizures, arrhythmia, stridor) is IV calcium gluconate. Calcium gluconate is preferred over calcium chloride for peripheral IV access because chloride is highly caustic to veins and can cause tissue necrosis on extravasation. One to two ampules of 10% calcium gluconate are infused slowly over 10-20 minutes with cardiac monitoring, because rapid infusion can cause bradycardia or cardiac arrest. After the bolus, a continuous calcium gluconate drip is maintained and titrated to keep the patient symptom-free while oral therapy is initiated.

Before giving calcium, always check magnesium. If magnesium is low, administer IV magnesium sulfate first. This step is non-negotiable. A patient with combined hypomagnesemia and hypocalcemia will remain refractory to calcium replacement until the magnesium deficit is corrected.

Chronic Management

The mainstay of long-term therapy is oral calcium supplements combined with calcitriol. Calcitriol is chosen over regular vitamin D (cholecalciferol or ergocalciferol) because patients with hypoparathyroidism lack the PTH needed to activate 1-alpha hydroxylase. Giving inactive vitamin D would be ineffective since the conversion step is impaired. Calcitriol has a rapid onset (1-2 days) and short half-life, allowing easier dose titration.

The target for serum calcium during chronic management is deliberately set in the low-normal range (approximately 8.0-8.5 mg/dL). The rationale is that without PTH, the kidney cannot adequately reabsorb calcium. Pushing serum calcium to mid-normal or high-normal levels will result in hypercalciuria, which leads to nephrolithiasis and nephrocalcinosis over time. This is why 24-hour urine calcium is monitored regularly; the target is below 300 mg/day.

Thiazide diuretics may be added as adjunctive therapy in patients with persistent hypercalciuria, because thiazides enhance distal tubular calcium reabsorption and reduce urinary calcium excretion.

Contraindications and Cautions

Avoid loop diuretics (furosemide) in hypoparathyroidism patients because they increase renal calcium wasting and worsen hypocalcemia. This is in direct contrast to their use in hypercalcemia, where the calciuric effect is desirable. If a patient with hypoparathyroidism needs a diuretic, use a thiazide instead.

05Differential Diagnosis and Distractors

The most important differential on exams is pseudohypoparathyroidism versus hypoparathyroidism. Both present with low calcium and high phosphate. The single discriminating feature is the PTH level: low in hypoparathyroidism, high in pseudohypoparathyroidism. The physical phenotype of Albright hereditary osteodystrophy (short stature, round face, shortened metacarpals) is a strong vignette clue pointing toward pseudohypoparathyroidism.

06Traps and High-Yield Pearls

The most common trap with hypoparathyroidism questions involves the postsurgical setting. A vignette describes a patient 24-48 hours after total thyroidectomy who develops perioral tingling and a positive Chvostek sign. Students who do not connect thyroid surgery to parathyroid gland injury may fail to recognize this as postsurgical hypoparathyroidism and instead attribute the symptoms to anxiety or hyperventilation. The key is that hyperventilation-induced hypocalcemia causes respiratory alkalosis (which shifts calcium onto albumin), whereas postsurgical hypoparathyroidism causes true hypocalcemia with low PTH.

Another frequent pitfall is the magnesium trap. A patient presents with refractory hypocalcemia despite adequate IV calcium. The vignette may mention a history of chronic alcohol use, prolonged PPI therapy, or aminoglycoside use. If you do not check magnesium and correct it first, the calcium will not budge. Test-writers love this scenario because it tests whether you understand that magnesium is required for PTH secretion and action.

Students also confuse the direction of phosphate across different causes of hypocalcemia. In hypoparathyroidism, phosphate is high (no PTH to excrete it). In vitamin D deficiency, phosphate is low (PTH is high and driving phosphaturia). This phosphate level is often the fastest way to differentiate between the two on a timed exam.

For treatment questions, remember that calcitriol is chosen over cholecalciferol because the 1-alpha hydroxylase step is PTH-dependent. If a question offers cholecalciferol as an answer choice alongside calcitriol, always pick calcitriol. Similarly, the target serum calcium is intentionally kept in the low-normal range to prevent hypercalciuria and renal stones, and this counterintuitive "don't normalize the calcium" concept is a favorite testing point.

Finally, know the ECG finding: prolonged QT interval due to lengthening of the ST segment. This is distinct from other causes of QT prolongation (such as hypokalemia, which prolongs QT by producing U waves and flattened T waves). Hypocalcemia-related QT prolongation is caused by delayed phase 2 of the cardiac action potential and predisposes to torsades de pointes.